Clinical Trial Update: Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update summarizes completed Phase 1/2 results evaluating vorinostat to prevent graft-versus-host disease after reduced-intensity, related-do…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies

Drugs mentioned

• Zolinza (vorinostat)

Snippet

Sponsor: Pavan Reddy, MD | Conditions: Hematologic Malignancies, Graft vs Host Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-11